MDP and mifamurtide (6) mitigate obesity and insulin resistance via suppressing the interferon regulatory factor 4 (IRF4) due to activation of NOD2, whereas iE-DAP (1) and its derivatives exhibits the opposite effect (Cavallari et al., 2017). Here, IRF4 is linked to obesity due to melanocortin 4 receptor deficiency.